A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.
Also called NCT04515849
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 248 participants
- Sponsor
- Registry
-
NCT04515849 -
2020-000255-12
-
- Other papers using this trial's data
- A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, Canada, Germany, Japan, New Zealand, Poland, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04515849. Randomized; double masking; primary purpose treatment. Start 2020-08-31 (actual); primary completion 2022-03-08 (actual). Results posted on 2025-01-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Cotadutide 100 micrograms
- Intervention (Drug)
- Cotadutide 300 micrograms
- Intervention (Drug)
- Cotadutide 600 micrograms
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04515849- Content hash
9542a940dcc736b8491b14b2c9074104d018f33c7c9b6e0807e8bd5b74a56ee2